参附注射液对接受化疗的肺癌患者生活质量的影响

[Influence of Shenfu Injection on the quality of life of lung cancer patients receiving chemotherapy].

作者信息

Long Shun-qin, Liao Gui-ya, He Wen-feng, Wang Bin, Deng Hong, Zhang Hai-bo, Chai Xiao-shu, Cai Jiao-zhi, Wu Wan-yin

机构信息

Department of Oncology, Guangzhou University of Traditional Chinese Medicine, Guangzhou, China.

出版信息

Nan Fang Yi Ke Da Xue Xue Bao. 2011 Dec;31(12):2090-2.

PMID:22200721

Abstract

OBJECTIVE

To evaluate the influence of Shenfu Injection (SHF) on the quality of life of patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.

METHODS

A total of 133 patients with NSCLC receiving at least two cycles of chemotherapy with taxol plus cisplatin (TP)/vinorelbine plus cisplatin (NP) or gemcitabine plus cisplatin (GP) were randomized into SHF pre-treatment group (with SHF given only in the first cycle) and SHF post-treatment group (with SHF given only in the second cycle). The Quality of Life Questionnaire-Core 30 (QLQ-C30) and the Functional Living Index-Cancer (FLIC) were used to evaluate the quality of life of the patients after the treatments.

RESULTS

Both of the groups showed improved quality of life after the treatments (P<0.01), but the improvements were more obvious in SHF pre-treatment group (P<0.05). SHF showed favorable effects in relieving such adverse effects as fatigue, nausea, vomiting and diarrhea associated with the chemotherapy.

CONCLUSION

SHF can improve the quality of life in NSCLC patients receiving chemotherapies.

摘要

目的

评估参附注射液（SHF）对接受化疗的晚期非小细胞肺癌（NSCLC）患者生活质量的影响。

方法

将133例接受至少两个周期紫杉醇联合顺铂（TP）/长春瑞滨联合顺铂（NP）或吉西他滨联合顺铂（GP）化疗的NSCLC患者随机分为SHF预处理组（仅在第一个周期给予SHF）和SHF后处理组（仅在第二个周期给予SHF）。采用生活质量核心问卷30（QLQ-C30）和癌症功能生活指数（FLIC）评估治疗后患者的生活质量。